Intralesional heterogeneity on PSMA PET–CT predicts mCRPC outcomes

IF 12.1 1区医学 Q1 UROLOGY & NEPHROLOGY

Nature Reviews Urology Pub Date : 2024-09-13 DOI:10.1038/s41585-024-00943-2

Maria Chiara Masone

引用次数: 0

查看原文本刊更多论文

PSMA PET-CT 显示的区域内异质性可预测 mCRPC 的预后

转移性耐受性前列腺癌（mCRPC）患者的肿瘤内异质性给治疗带来了挑战，因为肿瘤生长和对治疗的反应存在差异。目前可用的工具，如实体瘤反应评估标准（RECIST）和循环肿瘤DNA（ctDNA），是衡量患者治疗反应的有用方法，但无法对单个肿瘤病灶进行高分辨率评估。发表在《医学》（Med）上的一项新研究评估了68Ga-前列腺特异性膜抗原（PSMA）+18F-氟脱氧葡萄糖（FDG）配对正电子发射断层扫描-计算机断层扫描（PET-CT）捕捉区域内反应异质性（ILRH）和改善mCRPC患者风险分层的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Urology 医学-泌尿学与肾脏学

CiteScore

12.50

自引率

2.60%

发文量

123

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Urology is part of the Nature Reviews portfolio of journals.Nature Reviews' basic, translational and clinical content is written by internationally renowned basic and clinical academics and researchers. This journal targeted readers in the biological and medical sciences, from the postgraduate level upwards, aiming to be accessible to professionals in any biological or medical discipline. The journal features authoritative In-depth Reviews providing up-to-date information on topics within a field's history and development. Perspectives, News & Views articles, and the Research Highlights section offer topical discussions and opinions, filtering primary research from various medical journals. Covering a wide range of subjects, including andrology, urologic oncology, and imaging, Nature Reviews provides valuable insights for practitioners, researchers, and academics within urology and related fields.